Zydus Lifesciences' oncology facility receives favorable USFDA inspection report

Zydus Lifesciences Limited reported on September 21, 2025, that its oncology injectable manufacturing facility in SEZ1, Ahmedabad, received an Establishment Inspection Report (EIR) from the USFDA. The inspection, conducted from June 9 to 18, 2025, resulted in a classification of Voluntary Action Indicated (VAI).

This VAI classification marks an improvement from the facility's previous status of Official Action Indicated (OAI) in June 2024. The upgrade to VAI indicates a more favorable compliance standing with the USFDA's Good Manufacturing Practices (GMP).